SCHEMBL10274765

SCHEMBL10274765

Clc1ccc2c(c1-c1ccccn1)CCNCC2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 9/20 0.53
HTR2A P28223 8/20 0.53
HTR2B P41595 8/20 0.53
PNMT P11086 3/20 0.44
ADRA2A P08913 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
CCR1 P32246 2/20 0.39
CCR5 P51681 2/20 0.39
CCR8 P51685 2/20 0.39
HTR7 P34969 3/20 0.38
NISCH Q9Y2I1 1/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
METAP1 P53582 1/20 0.37
BLM P54132 1/20 0.37
HIF1A Q16665 1/20 0.37
DOHH Q9BU89 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12296722 0.83 HTR2C (0.50) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL2208485 0.79 HTR2C (0.43) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL14091673 0.75 HTR2C (0.48) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL12296161 0.74 HTR2A (0.50) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL3963915 0.74 HTR2B (0.47) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL10229387 0.74 GRM5 (0.48) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL14091665 0.73 HTR2C (0.53) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL10274888 0.73 HTR2C (0.54) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL2254513 0.73 HTR2C (0.46) HTR2CHTR2AHTR2BPNMTADRA2A
SCHEMBL10227500 0.73 NMT1 (0.47) HTR2CHTR2AHTR2BPNMTADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 HTR2C 1/4885HTR2A 4/4885HTR2B 6/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A HTR2C 1/4885HTR2A 4/4885HTR2B 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.